Search Results

In mice, a fatal brainstem tumor was cleared by injecting it with engineered T cells that recognized the cancer and targeted it for destruction. The Stanford discovery is moving to human trials.

In a clinical trial, participants were given an antibody to CD117, a cell surface marker, in an effort to wipe out their defective blood stem cells without high-risk chemotherapy or radiation.

CD47 is an important inhibitor of cancer-killing immune cells called macrophages. Now Stanford researchers have identified another, similar way to activate macrophages to destroy cancer cells.

Stanford researchers found that manipulating the gut microbe Clostridium sporogenes changed levels of molecules in the bloodstreams of mice and, in turn, affected their health.

“Humanized” mice are used to study human immune responses, but they are inadequate for stem cell studies, say Stanford researchers. Optimized models are needed for clinical decision-making.

An antibody to the cell receptor PD-1 may launch a two-pronged assault on cancer by initiating attacks by both T cells and macrophages, a Stanford study has found.

Effective anti-tumor activity requires a systemic, rather than only a local, immune response at the tumor site. A Stanford study may help clinicians pinpoint why only some cancer patients respond to immunotherapies.

Crystal Mackall will lead the university’s efforts to translate basic science discoveries into immune-based treatments for pediatric and adult cancers.

Researchers have developed a new way to use atomic force microscopy to rapidly measure the mechanical properties of cells, an advance that could pave the way for better understanding immune disorders and cancer.